Erythropoietic protoporphyria 

Erythropoietic protoporphyria
Classification and external resources
ICD-10 E80.0 (ILDS E80.010)
ICD-9 277.1
OMIM 177000
DiseasesDB 4484
eMedicine derm/473 
MeSH C06.552.830.812

Erythropoietic protoporphyria (EPP) is a relatively mild form of porphyria, although very painful, which arises from a deficiency in the enzyme ferrochelatase, leading to abnormally high levels of protoporphyrin in the tissue. The severity varies significantly from individual to individual.

Both autosomal dominant and autosomal recessive inheritance have been reported with this disorder.[1]

Contents

Presentation

A common symptom is very painful photosensitivity, manifesting itself as a burning sensation on the surface of the skin. This usually first presents in childhood, and most often affects the face and the upper surfaces of the hands and feet. Prolonged exposure to the sun can lead to edema and blistering. After many years, chronically sun-exposed skin may become thick and wrinkled. People with EPP are also at increased risk to develop gallstones[2]. In a small percentage of cases, protoporphyrin accumulates to toxic levels in the liver, leading to liver failure.

Treatment and prognosis

There is no cure for this disorder; however, symptoms can usually be managed by the simple expedient of limiting sun exposure. Protective clothing is also very helpful; however, since the photosensitivity results from light in the visible spectrum, most sunscreens (with the exception of light-reflecting substances such as zinc oxide) are of little use. Some individuals can decrease their sun sensitivity with daily doses of beta carotene; others gradually build a protective layer of melanin by regularly exposing themselves for short times to ultraviolet radiation. The most severe cases are sometimes treated with liver transplants.

Experimental treatments

Recently, an Australian pharmaceutical company has begun Phase III clinical trials with a melanocyte-stimulating hormone called melanotan (known by the International Nonproprietary Name afamelanotide, formerly CUV1647)[3] for EPP. [4][5]

History

Erythropoietic protoporphyria was first identified in 1960 by Magnus et al at the St John's Institute of Dermatology in London.[6]

References

  1. ^ Rüfenacht UB, Gouya L, Schneider-Yin X, Puy H, Schäfer BW, Aquaron R, Nordmann Y, Minder EI, Deybach JC (1998). "Systematic analysis of molecular defects in the ferrochelatase gene from patients with erythropoietic protoporphyria". American journal of human genetics 62 (6): 1341–52. doi:10.1086/301870. PMID 9585598. 
  2. ^ 12-160d. at Merck Manual of Diagnosis and Therapy Home Edition
  3. ^ "World Health Organisation assigns CUV1647 generic name" (PDF). Clinuvel (2008). Retrieved on 2008-06-17.
  4. ^ Erythropoietic - British Association of Dermatologists
  5. ^ Clinuvel receives approval to begin Phase III trials in EPPPDF (273 KB)
  6. ^ Magnus IA, Jarrett A, Prankerd TA, Rimington C (1961). "Erythropoietic protoporphyria. A new porphyria syndrome with solar urticaria due to protoporphyrinaemia". Lancet 2 (7200): 448–51. PMID 13765301. 

External links


v • d • e
Heme metabolism disorders (E80, 277.1, 277.4)
Porphyrin
Hereditary hyperbilirubinemia
 This genetic disorder article is a stub. You can help Wikipedia by expanding it.